Weekly Spotlight - 31.10.24

In the News

Autoimmune Liver Disease Unveiled by Tuberculosis Treatment: A Case Study

Two patients discovered autoimmune liver disease during tuberculosis treatment—surprise! This rare occurrence highlights the tricky task of distinguishing drug-induced liver injury from genuine autoimmune conditions. The article underscores the importance of considering autoimmune liver disease when faced with drug-induced liver injury. Who knew TB treatment could reveal such secrets?

Cirrhosis Burden in MENA: Trends and Interventions Needed

Cirrhosis in the MENA region has doubled over three decades, with a 114.9% rise in cases. While liver disease incidence climbs, death rates drop by 54.3%. MASLD is the main culprit, but public health efforts are making strides. Time for tailored interventions, folks!

ICOSL Deficiency: Severe Viral Infection and Autoimmune Hepatitis Case Study

In a twist of genetic fate, our patient with a rare ICOSL mutation faced a viral showdown and autoimmune drama. Despite the odds, he battled PML and autoimmune hepatitis, ultimately needing a liver transplant. This case highlights how ICOSL deficiency can seriously mess with immune defences.

Zetomipzomib Safe in Phase 2a Trial for Autoimmune Hepatitis Patients

Zetomipzomib, a potential game-changer for autoimmune hepatitis, has passed its safety check in a Phase 2a trial. With no major hiccups, the study continues, aiming for top-line data by 2025. Kezar Life Sciences is now focusing solely on this liver condition, ditching lupus nephritis. Exciting times ahead!

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!